Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)
Sweden flag Sweden · Delayed Price · Currency is SEK
2.600
-0.020 (-0.76%)
Jul 25, 2025, 5:29 PM CET

STO:NEWBRY Cash Flow Statement

Millions SEK. Fiscal year is Sep - Aug.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
May '25 Aug '24 Aug '23 Aug '22 Aug '21
Net Income
-11.33-15.41-19.43-14.67-6.06
Depreciation & Amortization
10.820.340.09-
Asset Writedown & Restructuring Costs
0.910.910.910.910.66
Stock-Based Compensation
-0.09-0.090.070.15-
Other Operating Activities
-1.11-0.130.25-0.13-
Change in Accounts Receivable
-7.07-7.07-11.161.26-2.1
Change in Inventory
-2.89-2.89-0.33-1.77-
Change in Other Net Operating Assets
13.330.146.12-0.853.07
Operating Cash Flow
-7.24-23.71-23.23-15-4.44
Sale (Purchase) of Intangibles
-2.91-2.91-0.86-24.4-25.18
Investment in Securities
-0.05-0.05---3.98
Investing Cash Flow
-1.81-2.95-0.86-24.4-29.17
Long-Term Debt Issued
-17.31-21.78-
Long-Term Debt Repaid
--2.03-0.72-7.13-
Net Debt Issued (Repaid)
15.2715.27-0.7214.64-
Issuance of Common Stock
18.1618.16-44.9547.94
Financing Cash Flow
5.2833.44-0.7259.5947.94
Net Cash Flow
-3.766.78-24.8120.1914.34
Levered Free Cash Flow
-13.69-4.46-21.63-31.69-
Unlevered Free Cash Flow
-12.56-3.5-21.63-31.69-
Change in Net Working Capital
4.09-7.729.86-1.2-
Source: S&P Global Market Intelligence. Standard template. Financial Sources.